# BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

> **NCT00962611** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 57 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Copanlisib (Aliqopa, BAY80-6946)

## Key facts

- **NCT ID:** NCT00962611
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11-19
- **Primary completion:** 2016-02-23
- **Final completion:** 2016-02-23
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2017-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00962611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00962611, "BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00962611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*